Category Archives: Physiology

Southampton is the best uni for Physiotherapy in the UK – The Tab

Uni league tables were released today and were up three places overall

The University of Southampton has been officially ranked the best uni for Physiotherapy in the country, it is also the second-best in the country for Occupational Therapy and Aural & Oral Sciences.

According to the Complete University Guide League Tables 2021 released today, the uni ranked 17th in the country alongside Manchester, and is three places up from last year. Southampton was ranked higher than numerous Russel Group unis such as Kings, Nottingham, York, Newcastle, Cardiff, and Liverpool.

The uni also had 12 other courses that were ranked within the top ten in the country. Southampton is the 4th best uni in the country for Electrical and Electronic Engineering, and ranked 5th for Music. For Nursing, Southampton is the 6th best in the country.

Other courses in the top ten include Iberian languages (Spanish and Portuguese), Mechanical Engineering, Geology, Anatomy and Physiology, Aeronautical and Manufacturing Engineering, Marketing, German, French and Civil Engineering.

Southamptons graduate prospects were rated 82.1/100, more than many unis that had ranked higher in the league table. Our research intensity was rated 0.90 higher than Oxfords 0.87.

Solent has been ranked 100th in the country, its highest ranking since 2017, whilst our Varsity rivals Portsmouth were ranked 61st.

Meet the Soton student who has set up a diverse greetings card business

Switch, Trago and karaoke: These are all your last normal Soton photos

Heres the last goodbyes every final year wishes they could have said to Soton

See the article here:
Southampton is the best uni for Physiotherapy in the UK - The Tab

Nearly 600 and Counting US Health Workers Have Died Of COVID-19 – Lake County Record-Bee

Nearly 600 front-line health care workers appear to have died of COVID-19, according to Lost on the Frontline, a project launched by The Guardian and KHN that aims to count, verify and memorialize every health care worker who dies during the pandemic.

The tally includes doctors, nurses and paramedics, as well as crucial health care support staff such as hospital janitors, administrators and nursing home workers, who have put their own lives at risk during the pandemic to help care for others. Lost on the Frontline has now published the names and obituaries for more than 100 workers.

A majority of those documented were identified as people of color, mostly African American and Asian/Pacific Islander. Profiles of more victims, and an updated count, will be added to our news sites twice weekly going forward.

There is no other comprehensive accounting of U.S. health care workers deaths. The Centers for Disease Control and Prevention has counted 368 COVID deaths among health care workers, but acknowledges its tally is an undercount. The CDC does not identify individuals.

The Guardian and KHN are building an interactive, public-facing database that will also track factors such as race and ethnicity, age, profession, location and whether the workers had adequate access to protective gear. The database to be released this summer will offer insight into the workings and failings of the U.S. health care system during the pandemic.

In addition to tracking deaths, Lost on the Frontline reports on the challenges health care workers are facing during the pandemic. Many were forced to reuse masks countless times amid widespread equipment shortages. Others had only trash bags for protection. Some deaths have been met with employers silence or denials that they were infected at work.

The number released so far reflects the 586 names currently in the Lost on the Frontline internal database, which have been collected from family members, friends and colleagues of the deceased, health workers unions, media reports, unions, among other sources. Reporters at KHN and The Guardian are independently confirming each death by contacting family members, employers, medical examiners and others before publishing names and obituaries on our sites. More than a dozen journalists across two newsrooms as well as student journalists are involved in the project.

Many of the health care workers included here studied physiology and anatomy for years. They steeled themselves against the long hours theyd endure. Emergency medical technicians raced by ambulance to help. Others did the cleanup, maintenance, security or transportation jobs needed to keep operations running smoothly.

They undertook their work with passion and dedication. They were also beloved spouses, parents, friends, military veterans and community activists.

None started 2020 knowing that simply showing up to work would expose them to a virus that would kill them.

This project aims to capture the human stories, compassion and heroism behind the statistics. Among those lost were Dr. Priya Khanna, a nephrologist, who continued to review her patients charts until she was put on a ventilator. Her father, a retired surgeon, succumbed to the disease just days after his daughter.

Susana Pabatao, one of thousands of Philippine health providers in the United States, became a nurse in her late 40s. Susana died just days after her husband, Alfredo, who was also infected with COVID-19.

Dr. James Goodrich, a renowned pediatric neurosurgeon, acclaimed for separating conjoined twins, was also remembered as a renaissance man who collected antique medical books, loved fine wines and played the didgeridoo.

Some of the first to die faced troubling conditions at work. Rose Harrison, 60, a registered nurse, wore no mask while taking care of a COVID-19 patient at an Alabama nursing home, according to her daughter. She felt pressured to work until the day she was hospitalized. The nursing home did not respond to requests for comment.

Thomas Soto, 59, a Brooklyn radiology clerk faced delays in accessing protective gear, including a mask, even as the hospital where he worked was overwhelmed with COVID-19 patients, his son said. The hospital did not respond to requests for comment.

The Lost on the Frontline team is documenting other worrying trends. Health care workers across the U.S. said failures in communication left them unaware they were working alongside people infected with the virus. And occupational safety experts raised alarms about CDC guidance permitting workers treating COVID patients to wear surgical masks which are far less protective than N95 masks.

The Occupational Safety and Health Administration, the federal agency responsible for protecting workers, has launched dozens of fatality investigations into health workers deaths. But recent agency memos raise doubts that many employers will be held responsible for negligence.

As public health guidelines have largely prevented traditional gatherings of mourners, survivors have found new ways to honor the dead: In Manhattan, a medical resident played a violin tribute for a fallen co-worker; a nurses union placed 88 pairs of shoes outside the White House commemorating those who had died among their ranks; fire departments have lined up trucks for funeral processions and held last call ceremonies for EMTs.

The Lost on the Frontline death toll includes only health care workers who were potentially exposed while caring for or supporting COVID-19 patients. It does not, for example, include retired doctors who died from the virus but were not working during the pandemic.

The number of reported deaths is expected to grow. But as reporters work to confirm each case, individual deaths may not meet our criteria for inclusion and, therefore, may be removed from our count.

You can read the first 100 profiles here online at https://khn.org/news/lost-on-the-frontline-health-care-worker-death-toll-covid19-coronavirus/. And if you know of a health care worker who died of COVID-19, please share their story with us.

Christina Jewett: ChristinaJ@kff.org, @by_cjewett

Melissa Bailey: @mmbaily

Read more:
Nearly 600 and Counting US Health Workers Have Died Of COVID-19 - Lake County Record-Bee

BSU names White as Dean of Individual and Community Health – Bemidji Pioneer

BEMIDJI -- Bemidji State University recently named Jim White as the new interim Dean of Individual and Community Health.

White is a BSU alumnus, professor and chair of the department of human performance, sport and health.

Dr. Whites academic training in community health, along with his administrative skills, position him well to lead the College of Individual and Community Health as we navigate the tricky waters of the COVID-19 situation, Allen Bedford, BSU provost and vice president for academic and student affairs, said in a release. "I greatly appreciate his willingness to step forward and he has already become a valued contributor to our fall 2020 planning.

Joining BSUs faculty in 2006, White has taught a variety of classes related to exercise testing and prescription, disease prevention, nutrition, exercise physiology and community health. He has served as chair for the Department of Human Performance, Sport and Health since 2016.

Prior to his role at Bemidji State, White spent nine years working as a clinical exercise physiologist specializing in cardiovascular and pulmonary rehabilitation. He holds certifications from the American College of Sports Medicine as a Certified Clinical Exercise Physiologist and the National Strength and Conditioning Association as a Certified Strength and Conditioning Specialist.

As an alumni of BSU I am hopeful that I can help my alma mater through this challenging time, White said in the release. I am looking forward to working with faculty and staff to ensure BSU is able to help students be the best they can be. I have first-hand experience in how BSU changes lives for the better and I hope to contribute to this positive change for our students.

White holds a bachelors degree in sport studies and management from Bemidji State, a masters of science in exercise physiology from the University of Kentucky and holds a doctorate in human development with an emphasis in wellness from North Dakota State University.

According to the release, his appointment as Dean of BSUs College of Individual and Community Health will begin Aug. 1 and extend through June 30, 2021.

Go here to read the rest:
BSU names White as Dean of Individual and Community Health - Bemidji Pioneer

RIE Trainee, Research Assistant, Exercise Physiology Lab job with NANYANG TECHNOLOGICAL UNIVERSITY | 209345 – Times Higher Education (THE)

RIE Trainee, Research Assistant (Exercise Physiology Lab) [#SGUnitedTraineeships]

Programme Summary

In conjunction with Workforce Singapore, NTU offer traineeships to support the SGUnited Traineeships Programme.The Traineeships are part of NTU's efforts to create relevant and meaningful traineeship opportunities for our nations new graduates entering the workforce during this difficult time.

About the Lab

The Exercise Physiology Laboratory conducts research to investigate the influence of habitual exercise on cardio-metabolic health and also on the promoters and inhibitors of physical work tolerance. The experiment trials are done mainly on humans and are conducted in ergometric laboratory, biochemistry laboratory and field environments.

Job Description

Requirements

The rest is here:
RIE Trainee, Research Assistant, Exercise Physiology Lab job with NANYANG TECHNOLOGICAL UNIVERSITY | 209345 - Times Higher Education (THE)

Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma – GlobeNewswire

CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Aerpio) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that it is hosting a key opinion leader (KOL) call on a novel mechanism for the treatment of glaucoma on Friday, June 12, 2020 at 11:30am Eastern Time.

The call will feature presentations by Dr. Paul Kaufman M.D. (University of Wisconsin) and Dr. Janey Wiggs, M.D., Ph.D. (Massachusetts Eye and Ear Infirmary and Harvard Medical School), who will discuss the current glaucoma treatment landscape and unmet medical needs, as well as the role of the Tie2 receptor in maintaining intraocular pressure. Drs. Kaufman and Wiggs will be available to answer questions at the conclusion of the event.

Aerpio's management team will also discuss its pipeline candidate, razuprotafib (formerly AKB-9778), for treating patients with glaucoma. Razuprotafib is a small molecule inhibitor that restores Tie2 activation in Schlemms canal and lowers intraocular eye pressure (IOP) via decreasing resistance to outflow from the eye. Razuprotafib has been formulated as a once or twice-daily topical eye drop and is entering a Phase 2 clinical trial in Q3:20, with top line data expected in Q1:21.

Aerpio recently announced positive and statistically significant intraocular eye pressure (IOP) reduction in a Phase 1b trial of 43 glaucoma patients, when razuprotafib was added to prostaglandin treatment. This data set is summarized here.

Paul Kaufman, M.D. is the Ernst H. Brny Emeritus Professor of Ocular Pharmacology and past Chair of the Department of Ophthalmology & Visual Sciences at the University of Wisconsin School of Medicine and Public Health, in Madison, Wisconsin. He is a physician-scientist, specializing in glaucoma and studying the mechanisms of aqueous humor formation and drainage, and the age-related loss of near vision. Dr Kaufman is a past President and past Executive Vice President of the Association for Research in Vision and Ophthalmology (ARVO), past President of the International Society for Eye Research (ISER), and has served on the US National Advisory Eye Council and numerous foundation and corporate scientific advisory boards. He has had continuous research funding from the US National Eye Institute for 40 years and from numerous private foundations, has authored over 375 original scientific articles and 75 book chapters, co-edited several textbooks including the most recent editions of Adlers Physiology of the Eye, and received numerous honors and awards including the Friedenwald Award from ARVO and the Balazs Prize from ISER. He was Editor-in-Chief of Investigative Ophthalmology & Visual Science from 2008 through 2012. Dr. Kaufman also holds an honorary Doctor of Medicine degree from Uppsala University in Sweden, where he was a post-doctoral research fellow.

Janey L. Wiggs, M.D., Ph.D. is a physician-scientist at the Massachusetts Eye and Ear Infirmary and Harvard Medical School. She is currently the Paul Austin Chandler Professor of Ophthalmology and is the Vice Chair for Clinical Research in Ophthalmology at Harvard Medical School. She also directs the CLIA-certified genetic testing laboratory at the Massachusetts Eye and Ear Infirmary and is a co-director of the Ocular Genomics Institute and co-director of the Glaucoma Center of Excellence. Dr. Wiggs received her B.A. and Ph.D. degrees in biochemistry from the University of California at Berkeley and her M.D. degree from Harvard Medical School. She did post-doctoral training in molecular genetics under the direction of Dr. Ted Dryja. Dr. Wiggs completed the ophthalmology residency at the Massachusetts Eye and Ear Infirmary and received fellowship training in glaucoma and also in medical genetics and is certified by the both the American Board of Ophthalmology and the American Board of Medical Genetics. Dr. Wiggs research program is focused on the discovery and characterization of genetic factors that contribute to the blinding eye disease glaucoma and is funded by the National Eye Institute (NEI) as well as other nonprofit foundations. She is investigating the genetic etiologies of both early-onset and adult forms of glaucoma and is the PI of the NEIGHBORHOOD consortium for gene discovery in primary open angle glaucoma and is a founding member of the International Glaucoma Genetics Consortium (IGGC). She has also participated in research programs funded by the US-INDO joint working group (NEI) and the NEI eyeGENE consortium. Dr. Wiggs was the inaugural chair of the Genetics Group for ARVO and is an ARVO gold fellow. She currently serves on the editorial boards of IOVS, JAMA Ophthalmology, Molecular Vision, Journal of Glaucoma, and Annual Reviews in Vision Science. She is a member of the scientific advisory boards for the Glaucoma Research Foundation, Research to Prevent Blindness and the Glaucoma Foundation, and is a past member of the Advisory Council of the National Eye Institute. She has received the Heed Award, the Heed/Knapp Award, the Research to Prevent Blindness Scholar Award, the AAO Honor Award, the Lew Wasserman Merit Award, the Alcon Research Award, the David L. Epstein award from the ARVO Foundation and was a winner of the NEI Audacious Goal competition. She is an elected member of the Glaucoma Research Society, the American Ophthalmological Society, the Academia Ophthalmologica Internationalis and the National Academy of Medicine.

About RazuprotafibRazuprotafib binds to and inhibits vascular endothelial protein tyrosine phosphatase (VE-PTP), an important negative regulator of Tie2. Decreased Tie2 activity contributes to vascular instability in many diseases including diabetes and more recently has been shown to contribute to the development of increased IOP and glaucoma. Razuprotafib activates the Tie2 receptor irrespective of extracellular levels of its binding ligands, angiopoietin-1 (agonist) or angiopoietin-2 (antagonist) and may be the most efficient pharmacologic approach to maintain normal Tie2 activation. Aerpio is studying a topical ocular formulation of razuprotafib in open angle glaucoma and exploring the utility of subcutaneous razuprotafib for diabetic complications, including diabetic nephropathy.

About Aerpio PharmaceuticalsAerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Recently published mouse and human genetic data implicate the Angpt/Tie2 pathway in maintenance of Schlemms canal, a critical component of the conventional outflow tract. The Companys lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP), is being developed as a potential treatment for open angle glaucoma, and the Company intends to investigate the therapeutic potential of razuprotafib in other indications. The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema (DME). The Companys third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924s exclusive licensor, Gossamer Bio, Inc. (Nasdaq: GOSS). For more information, please visit http://www.aerpio.com.

Forward Looking StatementsThis press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the Companys product candidates, including razuprotafib, ARP-1536 and the bispecific antibody asset, the clinical development plan therefor and the therapeutic potential thereof, the Companys plans and expectations with respect to razuprotafib and the development therefor and therapeutic potential thereof in addressing COVID-19 and the intended benefits from the Companys collaboration with Gossamer Bio for GB004, including the continued development of GB004 and the milestone and royalty payments related to the collaboration. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, the continued development of GB004 and maintaining and deriving the intended benefits of the Companys collaboration with Gossamer Bio; ability to continue to develop razuprotafib or other product candidates, including in indications related to COVID-19; the inherent uncertainties associated with the drug development process, including uncertainties in regulatory interactions, the design of planned or future clinical trials, commencing clinical trials and enrollment of patients in clinical trials; obtaining any necessary regulatory clearances in order to commence and conduct planned or future clinical trials; the impact of the ongoing COVID-19 pandemic on the Companys business operations, including research and development efforts and the ability of the Company to commence, conduct and complete its planned clinical activities; and competition in the industry in which the Company operates and overall market conditions; and the additional factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, as updated by our subsequent Quarterly Reports on Form 10-Q and our other subsequent filings with the SEC.

These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents the Company files with the SEC available at http://www.sec.gov.

Investors & Media:Gina MarekVP Financegmarek@aerpio.comOrInvestors:Irina KofflerLifeSci Advisorsikoffler@lifesciadvisors.com

Continue reading here:
Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma - GlobeNewswire

Letter to the editor: How to learn more about evolution – Hays Daily News

SundayJun7,2020at12:00PM

I am writing in response the John Wojakowskis editoral questioning evolution. It is easy to ask questions about and misquote articles on evolution, but it is not as easy to explain the complex science supporting it. It cant be done in an editorial, but I would like to refer your readers to several online articles that refute his propositions.

The first is Four Famous Transitional Fossils That Support Evolution by Shaena Montanari on http://www.forbes.com. Wojakowskis claim of circular reasoning is both bad science and bad logic.

The second article is The Fossil Fallacy by Michael Shermer at www. scientificamerican.com. Shermer states that we know evolution happened because of a convergence of evidence from such diverse fields as geology, paleontology, biogeography, comparative anatomy and physiology and many more. Fossils are but one line of inquiry.

The third article is Did 90% of Animal Species Appear about the Same Time as Human Beings published at the website Biologos. The conclusion Wojakowski stated is nowhere given in the article quoted by him. This article asks if the title claim is true and concludes The answer is no.

Wojakowskis report on the University of Michigans results reveal as lack of insight regarding the time frame of evolution. Evolution occurred over hundreds of millions of years, so 1.5 million is the blink of an evolutionary eye.

Science is too complex to be discussed in the editorial page, but I hope this rebuttal will be printed.

Janet Stotts, Topeka

More:
Letter to the editor: How to learn more about evolution - Hays Daily News

How ‘microgravity’ changes the bodies of astronauts – The Next Web

Being an astronaut looks like an exciting and glamorous career. But have you ever thought about the dangers that these people face by being exposed to extreme conditions, such as radiation and microgravity?

Living and working in microgravity can impact your whole body in different ways. On the other hand, the human body is capable of adapting its physiology to survive in diverse conditions.

[S]paceflight poses unique medical problems due to prolonged exposure to a combination of stressful stimuli, such as acceleration forces, radiation, and weightlessness. In particular, the latter condition is a critical feature of [spaceflight] and has effects on human physiology which were quite unexpected at the beginning of space exploration, TheNational Institutes of Healthdescribes.

Microgravity is the condition in which people or objects appear to be weightless.

You may have heard that there is no gravity in space. This is not quite true. In fact, a small amount of gravity can be found everywhere in space.

Gravity becomes weaker with distance. The International Space Station orbits our planet at an altitude between 320 and 400 kilometers (200 and 250 miles) above the Earth. At that altitude, Earths gravity is about 90 percent of what it is on the planets surface.

The real reason people and objects float in orbit is because that they are in free fall. On Earth, objects with more air resistance fall more slowly than objects able to slip through air more easily. In a vacuum, gravity makes objects fall at the same rate.

Sometimes,astronauts have to spend months in microgravity, so NASA and other space agencies carefully study the effects of microgravity in order to keep astronauts safe and healthy.

Astronauts who live on the space station spend months in microgravity. Astronauts who travel to Mars also would spend months in microgravity traveling to and from the Red Planet,NASA reports.

Under gravity, standing upright, fluid distribution creates higher arterial pressure in the feet (200 mmHg) than in the head (70 mmHg) relative to the heart (100 mmHg).

On Earth, with its normal gravity, all changes in posture such as when lying down, sitting, or standing as well as changes in activity levels such as through exercising require the heart and vascular system to regulate blood pressure and distribution by adjusting the heart rate (beats per minute), amount of blood ejected by the heart (or stroke volume), and constriction or dilation of the distributing arteries. These adjustments assure continued consciousness by providing oxygen to the brain or continued ability to work, with oxygen going to the working muscles,NASA describes.

Inspace, blood redistribution toward the head causes altered responses of the nervous and endocrine systems.

Besides that, the increased fluid within the skull increases brain pressure, causing hearing loss, brain edema, and deformation of the eye known as Spaceflight Associated Neuro-ocular Syndrome (SANS).

Acute exposure to microgravity can also cause symptoms of anorexia, vomiting, nausea, and headache, also known as space motion sickness. Fortunately,astronauts bodies can adaptto this in 4872 hours.

Because of microgravity, astronauts muscles are not required to support their body weight. Due to reduced use, they may suffer from muscle atrophy. This can make them unable to do physically demanding tasks while on a mission.

Its the same sensation you feel after spending the whole day laying down, and then try to take a walk right after. It feels like your muscles cant perform their job correctly.

In order to preventing thesehealth problems, astronauts exercise regularly, providing much-needed exercise in the microgravity environment.

Fluid distribution caused by microgravity affects the blood supply to the eye with an impact on its vascularization. Thats why someastronautsmay suffer from blurred vision, requiring them to wear glasses during the mission.

Gravity is the fundamental reference that tells us which way is down. To accomplish that function, we have receptors in our inner ears that act as our guidance system, helping to track the orientation of our bodies.

Microgravity makesastronautslose this reference, so they can feel disoriented and have difficulty coordinating their movements.

In space there is no gravitational force telling the inner ear which way is up and down. So while our eyes can certainly see a ceiling and floor in the spacecraft, our brains cannot register this. This causes nausea and dizziness. Some astronauts experience headaches and vertigo, theBBC reports.

Astronauts nervous systems usually adapt very quickly. By the third day of the flight, most of them cant feel the discomfort they felt when they first arrived in space.

Once they return to the Earth, they will have to face another process of adapting their physiological systems to gravity again.

On return to Earth, gravity once again pulls the blood and fluids into the abdomen and legs. The loss of blood volume, combined with atrophy of the heart and blood vessels that can occur in space, reduces the ability to regulate a drop in blood pressure that happens when we stand on Earth. Some astronauts experience orthostatic intolerance difficulty or inability to stand as a result of light headedness and/or fainting after return to Earth,NASA describes.

The human body is an incredible machine that can do amazing things. Of course, it requires a lot of training and dedication, and this is something at which astronauts excel.

This article was originally published on The Cosmic Companion byDr. Ana Luiza Dias.You can read this original piece here.

Astronomy News with The Cosmic Companion is also available as a weekly podcast, carried on all major podcast providers. Tune in every Tuesday for updates on the latest astronomy news, and interviews with astronomers and other researchers working to uncover the nature of the Universe.

Read more from the original source:
How 'microgravity' changes the bodies of astronauts - The Next Web

Letter to the editor: How to learn more about evolution – The Hutchinson News

SundayJun7,2020at12:00PM

I am writing in response the John Wojakowskis editoral questioning evolution. It is easy to ask questions about and misquote articles on evolution, but it is not as easy to explain the complex science supporting it. It cant be done in an editorial, but I would like to refer your readers to several online articles that refute his propositions.

The first is Four Famous Transitional Fossils That Support Evolution by Shaena Montanari on http://www.forbes.com. Wojakowskis claim of circular reasoning is both bad science and bad logic.

The second article is The Fossil Fallacy by Michael Shermer at www. scientificamerican.com. Shermer states that we know evolution happened because of a convergence of evidence from such diverse fields as geology, paleontology, biogeography, comparative anatomy and physiology and many more. Fossils are but one line of inquiry.

The third article is Did 90% of Animal Species Appear about the Same Time as Human Beings published at the website Biologos. The conclusion Wojakowski stated is nowhere given in the article quoted by him. This article asks if the title claim is true and concludes The answer is no.

Wojakowskis report on the University of Michigans results reveal as lack of insight regarding the time frame of evolution. Evolution occurred over hundreds of millions of years, so 1.5 million is the blink of an evolutionary eye.

Science is too complex to be discussed in the editorial page, but I hope this rebuttal will be printed.

Janet Stotts, Topeka

Visit link:
Letter to the editor: How to learn more about evolution - The Hutchinson News

Big Bang Theory: What is the Nobel Prize? What did Sheldon and Amy win a Nobel Prize for? – Express

He established the five prizes to be awarded for those working in Chemistry, Literature, Peace, Physics, and Physiology or Medicine in 1895.

The executors of the will, Ragnar Sohlman and Rudolf Lilljequist formed the Nobel Foundation and the first award ceremony took place in 1901.

Each winner is known as a laureate and as part of their award, they receive a gold medal, a diploma, and a sum of money that has been decided by the Nobel Foundation.

The Nobel Prize may not be shared by more than three individuals.

The Nobel Foundation website states as of 220, each prize is worth 9,000,000 SEK, which is approximately $935,366 and 716,224.

Originally posted here:
Big Bang Theory: What is the Nobel Prize? What did Sheldon and Amy win a Nobel Prize for? - Express

Fighting racism calls for action, not empty words – The Guardian

The statement from the college heads of Oxford University is a weak voice wafting over the perfectly trimmed college hedges answering the angry calls of protesters outside (Letters, 4 June). It is not good enough. Many colleges were built on the systematic abuse of black lives and livelihoods. The statement is passive and allows racism to breathe when black men and women cannot.

While recognising the role that education can play in building racial equality and fair inclusion of black voices, the heads fail to acknowledge that education perpetuates inequality and the silencing of black voices. If the Black Lives Matter movement is going to succeed, then we must recognise our past and present failures.

They write to reassert our belief in the need to promote, protect and advance equal dignity and respect, but to reassert statements only acknowledges that previous statements, like this one, have been ineffective. No marks are awarded for repetition in Oxford exams and I am not going to give them any for repeating hopes, wishes and acknowledgements, with no resultant action.

This statement comes from the high echelons of academia, yet I can only conclude that the authors are either out of touch or unable to admit their part in the problem. Despite the influence these heads wield, they have offered no suggestions or ideas to create effective and meaningful change. This statement means nothing other than we made a statement so weve done something, please stop shouting at us. This is a failure to support the ignored and unheard.

It is time to see statements of performative justice not just as ineffective, but offensive. And all this anger from a privileged white girl. Imagine the anger and pain of those who feel the effects of this prejudice constantly.Ginny GoughCambridge

Concerning the letter by the heads of Oxford colleges, may we make three points. First, while education, open discussion, etc, are useful tools to tackle racism, they are never enough. As many reports have pointed out, economic inequality also plays a crucial role, and all attempts should be made to reduce its blatant forms. Second, racism does not begin at the age of 18. It starts much earlier and we need to mobilise pre-university institutions as well. Third, we hope the authors are not using the term black just to mean black members of our community but in the modern political sense of non-whites. While recent events in the US continue to reveal the egregious treatment of members of the black community, one should not forget the Chinese, the Indians, the Pakistanis and the Jews, among others, who too have been frequent victims of systemic racism.Anant Parekh Department of Physiology, University of Oxford, Bhikhu Parekh Labour, House of Lords

In the surreal times we are living through, the simple act of breathing has taken on a disturbing dual symbolism. On the one hand, we have seen the tireless efforts of NHS staff to help Covid-19 patients breathe, while on the other, we witness the horrific events in the United States where police officers have killed a black man by denying him the ability to breathe (Trump and Biden offer starkly different visions with nation at a crossroads, 2 June).

Covid-19 has disproportionately affected minority communities in both the UK and the US. The persistence of racial inequality in both countries should be yet another wake-up call to put adequate measures in place to deal with structural racism. The question is will either government really be committed to addressing this issue?Dr Edie FriedmanExecutive director, Jewish Council for Racial Equality

Join the debate email guardian.letters@theguardian.com

Read more Guardian letters click here to visit gu.com/letters

See the original post:
Fighting racism calls for action, not empty words - The Guardian